Tempus AI, Inc. (TEM)
Tempus AI, Inc. (TEM) Analyst/Investor Day Transcript
Tempus AI, Inc. (TEM) Analyst/Investor Day Transcript
Tempus AI: Taking Advantage Of Investor Myopia
Tempus AI is a precision medicine leader leveraging AI and a unique data estate, with significant partnerships and a rapidly growing contract backlog exceeding $1 billion. TEM's recent share price decline and controversy around profitability have compressed valuation, creating an attractive entry point for risk-tolerant investors seeking positive alpha. Data licensing revenues rose nearly 70% last quarter, with foundation models and AI-driven products fueling high-margin growth and reinforcing TEM's competitive moat.
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Tempus AI, Inc. is positioned as a data-driven precision medicine leader, leveraging AI and a vast multi-modal patient database to drive diagnostics and biopharma partnerships. TEM's dual business model—genomic diagnostics and data licensing—creates network effects, with diagnostics feeding a proprietary data moat that underpins high-margin, scalable growth. Despite a 50% share price decline from highs and ongoing unprofitability, TEM's rising revenues, expanding gross margins, and robust contract pipeline support a strong buy rating for long-term investors.
Tempus AI: Another Post-Earnings Dip Worth Buying
Tempus AI presents a compelling long-term opportunity, with strong data adoption and an expanding addressable market beyond Oncology. Q1 showed mixed results: robust Oncology testing, Hereditary weakness, decelerating revenue growth, but narrowing losses and gross margin expansion. Record $1.1B TCV and 126% net revenue retention underscore Tempus AI's durable value proposition and client stickiness.
TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down
Tempus AI posts narrower Q1 loss and strong 36% revenue growth, but shares slide after-market as operating loss and rising costs weigh on sentiment.
Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript
Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript
Tempus AI (TEM) Reports Q1 Loss, Beats Revenue Estimates
Tempus AI (TEM) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago.
Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus AI Stock Before Q1 Earnings Release: To Buy or Not to Buy?
TEM faces pressure ahead of Q1 earnings as macro headwinds, high valuation and estimate trends cloud its near-term investment appeal.
Tempus AI Nears Profitability as Operating Leverage Emerges
TEM nears profitability as gross profit surges and EBITDA turns positive, but persistent GAAP losses keep focus on long-term operating leverage.
Tempus AI Expands Strategic Partnership Amid Oncology Boom
TEM expands GenoPredicta rollout and deepens oncology partnerships, leveraging AI and WGS to advance cancer diagnostics and research.
Tempus AI, Inc. (TEM) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Tempus AI, Inc. (TEM) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
